News FDA approves UCB’s Cimzia in plaque psoriasis The US FDA has approved a label extension for UCB’s Cimzia (certolizumab pegol) for adults with moderate-to-severe plaque psoriasis
Oncology ASCO 2026: All about DNA damage response, with Luke Piggot Luke Piggot, a principal scientist at Debiopharm, shares some recent data and news about the company's work in DNA damage repair inhibitors.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
